The University at Buffalo (UB) is looking for volunteers to join the Long COVID Connection. Our goal is to build a collection of completed questionnaires of local Western New York community members who are experiencing the effects of long COVID-19 infection. The Long COVID Connection will help us to share news about long COVID-19 as we learn more about this condition. UB researchers will also use completed questionnaires to communicate information about studies recruiting volunteers with long COVID-19. Read More

Adults over the age of 18 years old
Experiencing symptoms of long COVID-19 infection
Live in one of the eight counties of Western New York (Niagara, Erie, Chautauqua, Cattaraugus, Allegany, Wyoming, Genesee, and Orleans)

The University at Buffalo (UB) Department of Rehabilitation Sciences is looking for adult volunteers with and without spinal cord injuries to participate in an exercise study. The goal of the study is to learn more about the brain and bodily responses to exercise in people with and without spinal cord injuries. The results of this study will hopefully improve the quality of life for adults with spinal cord injuries. Read More

Adults between the ages of 18-55 years old Adults with a spinal cord injury (at least 6 months after the initial injury) Adults without a spinal cord injury Reliable transportation to attend two study visits on the UB South Campus (at Main Street and Bailey Avenue)

This study is recruiting volunteers for a dental study through the University at Buffalo (UB) Microbiome Center in the UB School of Dental Medicine. The study team is researching if they can make accurate copies of bacteria patterns in mouth plaque (the “stuff” that collects between gums and teeth). The results of the study will help dentists to better understand how gum disease develops and comes back over time. Read More

1. At least 21 years old 2. Have at least sixteen (16) teeth 3. Not currently pregnant 4. Not currently wearing braces or orthodontic appliances

The UB Jacobs School of Medicine and Biomedical Sciences, Division of Behavioral Medicine (DBM) is looking for adult volunteers to participate in the EPPIC (Easing Pelvic Pain Interventions Clinical Research Program). The goal of this National Institutes of Health (NIH)-funded study is to determine the effectiveness of different behavioral therapies for controlling urologic chronic pelvic pain syndrome (UCPPS), why they work, for whom they are most effective, and durability of treatment gains (or how long they last). This is a non-drug treatment study and volunteers will receive payment for their participation in the study. Read More

1) Male or females between the ages of 18-70 years old 2) Experience pelvic pain symptoms for at least 3 months 3) Diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) or chronic prostatitis/chronic pelvic pain syndrome (CP/CPP) 4) Access to a telephone and computer/smartphone 5) Reliable transportation

This study is recruiting patients diagnosed with rapid-onset dystonia-parkinsonism (RDP). RDP is a rare movement disorder. It has symptoms of both dystonia (lasting muscle contractions) and Parkinson’s Disease (presence of tremor in one hand and a stiffness or slowing of movement). Patients may develop RDP suddenly or gradually over time. Read More

1) Patients with known/suspected RDP gene mutation OR those who have been identified as carriers/family members of someone with an RDP gene mutation 2)Patients who were previously enrolled in an earlier version of this study 3) 18 months of age or older 4) Access to Wi-Fi and a smart device (for example, a smartphone, laptop, tablet)

This study is for children ages 7 – 17 years old admitted to the Oishei Children’s Hospital emergency room (ER) who are experiencing nausea/vomiting. The goal of the study is to see if a different treatment (inhaled isopropyl alcohol) works better than the medication typically used (Zofran) for treating nausea/vomiting in pediatric patients. Read More

1. 7-17 years old

2. Chief complaint of nausea or vomiting

3. Weight >=15 kg (~33lbs)

4. BARF (nausea severity score) >=4/10

5. Admitted to the Oishei Children's Hospital emergency room

This study is being used to evaluate a new troponin blood test. Troponin blood tests are used in emergency departments as part of the diagnosis for heart attack. Patients presenting to the emergency department with chest pain or heart attack equivalent symptoms will be invited to participate. Blood draws will occur 5 times during the patient's emergency department visit. The results of the blood test will not be available to the treating provider, and will have no effect on patient care. Read More

1. Patients seeking emergency care in participating emergency department

2. Signed Informed Consent

3. Age: 20 or more years

4. Subjects demonstrating symptoms suggestive of acute coronary syndrome and/or myocardial ischemia or Asymptomatic subjects or patients with atypical symptoms in whom myocardial infarction is being suspected

5. Troponin or other cardi...

For 18-45 year old women undergoing gynecology surgery at Kaleida Health. A sliver of tissue and a tablespoon of fluid will be removed from womb lining which will take less than 5 minutes. This tissue and pelvic fluid will be used to examine cells, and measure hormones / inflammatory proteins. Patients will also be told whether or not there is endometriosis. Read More

-Reproductive age women (18-45 years old)
-Regular menstrual cycles
-Undergoing indicated gynecological surgery, including tubal sterilization, evaluation of pelvic pain or pelvic mass

This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period. Read More

1) History of chronic stable, NYHA class II to IV CHF 2) NT-proBNP 600 - 6000 3) LVEF of <40% assessed within 12 months before randomization

Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More

1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens